

REVIEW

Computational methods and applications for quantitative systems pharmacology

Fuda Xie^{1,2}, Jiangyong Gu^{1,2,*}

¹ The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China

² Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou 510006, China

* Correspondence: gujy@gzucm.edu.cn

Received June 29, 2018; Revised August 8, 2018; Accepted August 31, 2018

Background: Quantitative systems pharmacology (QSP) is an emerging discipline that integrates diverse data to quantitatively explore the interactions between drugs and multi-scale systems including small compounds, nucleic acids, proteins, pathways, cells, organs and disease processes.

Results: Various computational methods such as ADME/T evaluation, molecular modeling, logical modeling, network modeling, pathway analysis, multi-scale systems pharmacology platforms and virtual patient for QSP have been developed. We reviewed the major progresses and broad applications in medical guidance, drug discovery and exploration of pharmacodynamic material basis and mechanism of traditional Chinese medicine.

Conclusion: QSP has significant achievements in recent years and is a promising approach for quantitative evaluation of drug efficacy and systematic exploration of mechanisms of action of drugs.

Keywords: quantitative systems pharmacology; network modeling; multi-scale platforms; traditional Chinese medicine

Author summary: Quantitative systems pharmacology (QSP) is an emerging discipline that integrates diverse data to quantitatively explore the interactions between drugs and multi-scale systems including small compounds, nucleic acids, proteins, pathways, cells, organs and disease processes. This review is an attempt to introduce the computational methods for QSP, including ADME/T (absorption, distribution, metabolism, excretion and toxicity) evaluation, molecular modeling, logical modeling, network modeling, pathway analysis, multi-scale systems pharmacology platforms and virtual patient as well as their applications in medical guidance, drug discovery and explorations of pharmacodynamics material basis and mechanism of traditional Chinese medicine.

INTRODUCTION

Systems pharmacology (SP) combines systems biology approaches and computational methods to enable drug discovery for complex diseases and understand mechanisms of action (MoA) of drugs [1–4]. SP provides holistic approaches to facilitate the prediction of effectiveness and safety of molecules during the process of drug discovery. The human body is a complicated and integrated system, which can be regarded as biological networks [5]. Methods that can be applied to quantitative evaluation of the complex interactions between drugs and disease-related systems are urgently needed. The etiology and pathogenesis of complex diseases such as cancer,

schizophrenia, and Alzheimer's disease concern lots of genes, gene products, small molecules and pathways, and there are still challenges in disease treatment [6–10]. Quantitative systems pharmacology (QSP), as a branch of SP, is an emerging approach to understand the interaction mechanism between drugs and the body and to predict the pharmacological effects of drugs [11–13]. QSP integrates diverse data, including preclinical and clinical information to analyze dynamic interactions between a drug or drug combination and multi-scale biological systems, that aims to understand the behavior of the systems as a whole [14,15]. It can also provide quantitative insights into biological and pharmacological processes [16]. QSP gets more and more attention in pharmacological research and

pharmaceutical industry [13,17,18].

QSP is usually described as three steps: gathering enough information such as disease-related targets, biomarkers, pathways, drug-target interactions and phenotypic characteristics; building a primary model based on the above information, calibrating and validating the model by comparing predictions with preclinical and clinical data [19,20]. QSP is a promising approach to quantitatively explore the interactions between drugs and the systems including targets, pathways, cells and organs and provides a comprehensive insight into the underlying mechanisms of drug action [21].

QSP has been becoming a discipline and the research in QSP involves describing pharmacokinetic/pharmacodynamic (PK/PD) characteristics of drugs, identifying the targets and drug-target interactions and investigating the factors that cause differences in the omics data of cells, tissues and patients [22,23]. Traditional drug discovery holds the thought “one drug, one target, one disease” and tries to treat the disease by adjustment of a single target which is responsible for the disease. This simple strategy pushes drug design to focus on selective drugs for specific targets. With the in-depth understanding of biological processes and pathogenesis, the disease phenotypes often represent a complex regulating network with multiple targets, pathways and cell signal transduction [1,24–29]. A single target can also be related directly or indirectly with many kinds of diseases [30,31]. QSP integrates the understanding of complex networks of diseases and adopts quantitative analytical and predictive methods, which provides a feasible approach for the development of new multi-target drugs and exploration of their MoAs.

This review is an attempt to introduce the computational

methods and applications for QSP, including ADME/T (absorption, distribution, metabolism, excretion and toxicity) prediction, network pharmacology and multi-scale systems pharmacology platforms (Table 1).

METHODS FOR QSP

Molecular-level evaluation and simulation

At the molecular level, QSP focuses on the evaluation of molecular properties and identification of drug-target interactions. These methods such as ADME/T analysis, chemical space analysis, drug-likeness evaluation can provide information about the characteristics of metabolism of drugs or compounds. The widely used PK/PD models provide the most basic data about drug absorption, distribution, metabolism, excretion and toxic characteristics [32,69–71]. PK and PD data indicate how drugs change *in vivo* over time and the characteristics of targets to elucidate the mechanism of drug action [14,32–34,69]. For example, Rostami-Hodjegan took into account the knowledge of physiology and biology based PK to predict the effects of intrinsic and extrinsic factors of drugs [69].

There are several computational methods to simulate the drug-target interaction such as molecular docking, molecular dynamics simulation, machine learning and similarity analysis. Molecular docking and molecular dynamics simulation are feasible approaches for drug discovery, which give insights into the conformation of drug-target interaction and provide theoretical basis for virtual screening of lead compounds [37,38,72,73]. Rational drug design can be carried out by simulating the characteristics of targets and interactions with drugs

Table 1 Computational methods for QSP

	Method classification	Description	Refs.
Molecular level	Evaluation of molecular characteristics	Providing information about molecular properties of drugs (ADME/T, PK/PD model, chemical space analysis and drug-likeness evaluation)	[1–4,32–36]
	Identification of drug-target interaction	Predicting and evaluating drug/compound-target interaction (molecular docking, molecular dynamics simulation, machine learning and similarity analysis)	[37–42]
Network level	Drug-target network analysis	Analyzing the interactions between drugs and targets	[43–45]
	Protein-protein interaction network analysis	Analyzing topological structures of complicated protein–protein interaction network	[46]
	Pathway analysis	Investigating the connections between drug targets and regulatory networks of diseases, and evaluating drug efficacy in the context of pathway network	[47–50]
Systems level	Logical modeling	A mechanism-based mathematical method to endow the object with logical structure.	[51]
	Multiscale systems pharmacology platform	Evaluating the treatment effects of therapeutic regimens and exploring the MoA by integrating preclinical/clinical data of drugs and disease phenotypes (TCMSP, Virtual Tumour, CancerHSP, <i>etc.</i>)	[52–64]
	Virtual patient	A simplified model to translate complex biological processes into a series of intuitive equations	[65–68]

and the high-throughput virtual screening is accomplished by analyzing the binding affinity between compound and target. For example, Omer discovered two novel antiviral molecules (Calanolide A and Chaetochromin B) and their target HRAS by molecular docking and molecular dynamics simulation [73]. In our recent work, a binding energy-weighted polypharmacological index was introduced to evaluate the importance of target-related pathways which had close correlation with the pathogenesis of psoriasis [74].

Machine learning and similarity analysis are another two important approaches to explore drug-target interactions and drug-drug interactions. Machine learning is a method used to improve the performance on a specific model with data, and plays an important role in systems pharmacology [39–42]. For example, Chiu and Xie integrated coarse-grained normal mode analysis with multi-target machine learning to predict protein-ligand binding/unbinding kinetics accurately [41]. Yang *et al.* constructed three best-performing model to screen inhibitors for P-glycoprotein (P-gp) by machine learning algorithm, and these models were employed as a virtual screening tool for identifying 875 potential P-gp inhibitors and 15 inhibitor-rich herbs from TCMSP [75]. Compounds that have similar structures would have similar functions. Predicting targets for a new molecule by comparing the similarity with active compounds whose targets are known is a traditional method. BindingDB [76] and BATMAN-TCM [77] are two famous web-server which can predict drug-target interaction by analyzing molecular similarity.

Network modeling and pathway analysis

Network modeling integrates disease-related genes, pathways, targets and drugs into a complex network model and provides frameworks for understanding of how regulation arises from the interactions between cellular components [1,2,43–45]. The biological systems can be regarded as networks, where nodes represent molecular entities (DNA, RNA, protein and small compound) and processes, edges represent the relationships between nodes. Important nodes and edges in the network can be identified by network analysis. The change of global characteristics of network can be determined by network dynamics simulation. The network model can provide important information such as key targets in regulatory networks, the mechanism of interactions between drugs and targets. The results of network modeling can provide theoretical basis and guide for the development of multi-target drug, drug combination and credible options for personalized treatment as well as a feasible way to explore the pathogenesis of diseases. These network-based approaches are useful in understanding the basis for

cancer combination therapy [3], discovering treatment regimens for optimal efficacy [78], identifying the origins of drug induced adverse events [79–81], and indicating how drug combinations can mitigate serious adverse events [82]. For example, Wu developed an integrated network and cheminformatics tool (SDTNBI) for systematic prediction of drug-target interactions and drug repositioning [83,84]. Wang applied network topologies and dynamics parameters to obtain two potential weak-binding drug candidates whose effects were validated by *in vitro* experiments so as to provide a feasible way for drug discovery [85].

Pathway analysis is an approach to investigate the therapeutic mechanism by analyzing the connections between drug targets and regulatory networks of diseases [47]. It is a universal way that provides various information as the basis of many models in QSP [86]. Topological analysis is usually used to measure the importance of genes to simplify the complex pathway network into a structured collection of related genes. It can effectively reduce the difficulty of modeling and analyzing the pathway network which is responsible for the disease phenotype. But it may reduce the accuracy of the results as it ignores some potentially valuable information such as the connections of genes that belong to different pathways and potential pathogenic genes [87]. Nie *et al.* studied the regulation mechanism of Toutongning capsule by analyzing the signaling pathway of the migraine and the results showed that 19 active compounds and 8 targets played a crucial role in the treatment of migraine through TNF pathway [88].

We have developed a pathway network-based method by combining network modeling and molecular docking to evaluate drug efficacy. Network efficiency (*NE*) and network flux (*NF*) are both global measures of the network connectivity. We used *NE* and *NF* to quantitatively evaluate the inhibitory effects of compounds. The edge values of the pathway network were reset according to the Michaelis-Menten equation, which used the binding constant and drug concentration to determine the degree of inhibition of the target protein in the pathway. The dose-response curve was sigmoid and the predicted effects of compounds were in good agreement with experimental results [5,48–50]. Moreover, This approach can be used for predictions of drug combination and drug repositioning [5,89].

Systems-level methods

Logical modeling

Logical modeling is a kind of mathematical method based on the mechanism which can endow the object with logical structure. It can provide insights into a variety of

phenomics profiles through the analysis of the logical relationship between phenotype and mechanism [51,90–92]. This modeling method can be established according to the known information of the biological process and optimized by calibrating the modeling results with experimental data. Then altering parameters of the model to simulate the changes of biosystems to obtain various outcomes which can provide useful information and meaningful predictions to the process. This approach can provide reasonable way to build enormous biological network models in lack of various preclinical and clinical data by predicting the logical relationship. However, it is important to be aware of the simplification in this mechanism-based simulation which would cause the impossibility of representing the complexity and diversity of biological systems [51]. Poltz *et al.* built a discrete logical model of signal transduction of DNA damage response to screen target proteins for DNA-damaging agents that could be suitable for radio- and chemotherapy, and contributed to the design of more effective therapies [90].

Multi-scale systems pharmacology platforms

QSP takes the whole body as the starting point of research to seek the relationship between drug administration and disease to speculate the underlying mechanisms. It is also used to guide personalized medicine by integrating genomics knowledges. Multi-scale systems pharmacology focuses on disease-related multiple drugs, targets, pathways, biomarkers and phenomics. Several multi-scale systems pharmacology platforms have been developed such as TCMSP [52], Virtual Tumour [53], CancerHSP [54], C²Maps [55], VisANT 4.0 [56], PDTTCM [57], CVDHD [58], Lipoprotein Metabolism and Kinetics (LMK) Platform [59], Rheumatoid Arthritis PhysioLab platform [60], and others [61–64].

TCMSP is a unique systems pharmacology platform of Chinese herbal medicines and sparks a new interest in the search of candidate drugs from TCM [52]. TCMSP contains chemicals and their pharmacokinetic properties, targets and drug-target networks, drug-target-disease networks to capture the relationships between drugs, targets and diseases. Virtual Tumour Preclinical platform integrates available PK and cell cycle PD measurements for chemotherapeutic and targeted cancer treatment agents into a model of cell cycle and xenograft tumor growth [53]. Musante *et al.* reported an Immuno-Oncology (I-O) platform to investigate the effects of two kinds of regimens for cancer and suggest possible applications based on clinical data and analysis of mechanism [59]. Kirouac *et al.* developed a multi-scale

systems model of ErbB signaling to support the preclinical investigation of a bispecific antibody targeting HER2 and HER3 in cancer [93]. Another important QSP modeling platform is the DILIsym® which is developed by the non-profit Hamner Institutes of Health Sciences. It can be used for drug development [94], explaining the mechanisms of hepatotoxicity [95] and liver toxicities [96]. PDTTCM [57] and CVDHD [58] are two online servers that developed for psoriasis and cardiovascular disease, respectively. PDTTCM and CVDHD integrated medicinal herbs, natural products, disease-related proteins, docking results and clinical biomarkers. By using virtual screening and network pharmacological methods, PDTTCM and CVDHD streamline drug/lead discovery from natural products and explore the action mechanism of medicinal herbs and formulae [57,58].

These platforms that combine the preclinical/clinical data of many aspects and a variety of disease phenotypes are able to evaluate the treatment effects of therapeutic regimens and explore the MoA. These models are also applicable to different diseases after appropriate adjustment. However, the development of these platforms requires a certain depth of clinical research on the diseases and a wider range of preclinical and clinical data [59].

Virtual patient

Using QSP model to translate complex biological processes into a series of intuitive equations is a promising way to get insights into curative effects in drug discovery and disease treatment. However, the preclinical and clinical data for the establishment of models is lacking in some aspects. Many scientists simplified the models by alternative parameterization to reduce the need for data, and this method is also called “virtual patient” [65–68,97]. Moreover, a mechanistically-based weighting method to match clinical trial statistics at population level was introduced in a comprehensive analysis (virtual population) [60]. Geerts *et al.* used a mechanism-based QSP platform, virtual human patient, to simulate the biological processes of Alzheimer’s disease and to build a tool to realize personalized drug treatment [66]. Allen *et al.* [68] developed a new approach to generate virtual population without the step of weighting. This approach includes following steps: define plausible ranges for model parameters and initialize parameters; calibrate the model by comparing the prediction with database, then repeat the selection and optimization steps until the available model patients are plentiful enough. Finally, a credible virtual population model is constructed after calculating probability of inclusion into virtual population and optimizing the inclusion rate.

APPLICATIONS

Drug discovery

The strategy of drug discovery has been shifting from searching selective drug for single target that aimed to decrease side effects into looking for drugs that can rebalance the biological processes and regulatory networks [1,25,98–104]. The *in vivo* dynamics and kinetics of drug-target interactions can be simulated and evaluated by establishing QSP models to reduce the cost of money and time in a certain extent comparing with the traditional *in vivo* experiments [78,105]. QSP models integrate multiple regulatory networks of disease-related biological processes and build platforms for screening. The applications of these platforms can increase the efficiency of high-throughput screening of candidate compounds and reduce the time required to study the links between drugs and complex networks. Unwanted side effects and toxicity of candidate drugs can be evaluated by adverse drug reactions [82,106–109] and toxicity models [70,110]. Liu *et al.* [111] applied a comprehensive systems approach to identify 73 bioactive components from licorice and 91 potential targets for this herb. The mechanism of this herbal medicine by mapping drug-target and drug-target-disease networks was further elucidated. Luo used a network-based multi-target computational approach to screen potential anticancer drugs from natural products and predict the interactions between anticancer drugs and cancer-related targets [112]. Archimedes model is a human physiology-based statistical disease progression model to simulate the effect of treatments for cardiometabolic diseases [113,114]. These works all make it easier and cheaper to find new effective drugs.

Medical guidance

QSP models are utilized to inform different questions in pharmacology, such as MoA exploration, efficacy evaluation, translational medicine and drug discovery. The QSP modeling of drug metabolizing process usually uses a time dependent equation. QSP models can be built on a time scale while the time of reaction can be as short as action process of quick-acting drugs and as long as the generation and deterioration of chronic diseases. QSP modeling approaches can address challenges in the translation of preclinical findings to the clinical applications [115–117]. Instead of analyzing the instantaneous outputs of models, researchers usually use frequency-domain response analysis in mathematics to explore the process of change under perturbation (treatment of disease) at the systems level [118]. Taylor *et al.* analyzed 14 distinct PD models of four class (indirect response,

auto regulation, precursor-pool and moderator-mediated feedback) to evaluate the practicability of frequency-domain response analysis method [118].

There are also many other kinds of medical guidance provided by QSP models. Visser *et al.* simulated and optimized *in vivo* dosing regimens by informing both preclinical and translational evaluation of single drug and combination therapy [119]. Geerts *et al.* contributed a lot in development of schizophrenia treatment such as predicting the effect of existing drugs and developed a mechanism-based QSP model of a relevant key cortical brain network with schizophrenia pathology to gain insights of cognitive deficits in schizophrenia [97,120–122]. Vega-Villa *et al.* developed a QSP model to characterize metabolome of nitric oxide after a long-term infusion of sodium nitrite that would be valuable for nitrite dosing selection in clinic [123]. John *et al.* investigated the mechanisms of anxiolytic drugs on hippocampal electric patterns and interpreted the stimulus-frequency relationship of hippocampal theta [124]. Rostami-Hodjegan developed a physiologically based pharmacokinetic model to guide administration of oseltamivir in pediatric patients [69,125]. Recently, Kaddi *et al.* presented a multiscale and mechanistic QSP modeling of acid sphingomyelinase deficiency and the enzyme replacement therapy that quantitatively assessed systemic pharmacological effects in adult and pediatric patients at molecular-level, cellular-level, and organ-level effects [126]. Other works contributed to expand knowledge of disease processes by phenotypic screening and developing personalized medicine [47,127–129].

QSP in TCM

Systems pharmacology methods are frequently used in exploration of pharmacodynamic material basis and MoA of traditional Chinese medicine (TCM) [130–139]. The recent applications of these QSP methods in TCM are summarized in Table 2. For example, Li *et al.* dissected the mechanism of the addition and subtraction theory of traditional Chinese medicine by building a SP platform to contrast and analyze the variation of kinetic parameters and targets of active compounds in Xiao-Chaihu-Decoction and Da-Chaihu-Decoction [180]. Yao *et al.* investigated the different pharmacological effects of herbs in Ma-huang decoction to elucidate the combination principles of TCM [158]. Zhou *et al.* investigated the underlying mechanisms of efficacy of herbs for eliminating blood stasis and tonifying Qi by linking the drugs, targets and diseases to obtain compound-target-disease associations for reconstructing the biologically-meaningful networks based on systems pharmacology methods [181]. Zhao *et al.* built a pharmacological system model of Bufei Jianpi formula by absorption filtering, network targeting,

Table 2 Selected applications of QSP methods in TCM

TCM	Computational method	Refs.
Acori Tatarinowii Rhizoma and Curcumae Radix	Data mining, pathway enrichment, network analysis	[140]
<i>Erigeron breviscapus</i>	ADME pharmacokinetic screening, target fishing, protein-protein interaction network analysis and <i>in vitro</i> experiments verification	[141]
<i>Eucommia ulmoides</i> Oliv.	Drug-likeness evaluation, oral bioavailability prediction, multiple drug targets prediction and network pharmacology techniques	[142]
<i>Hedyotis diffusa</i> Willd.	Active component gathering, target prediction, related gene collection, gene enrichment analysis and network analysis	[143]
Licorice	Oral bioavailability screening, drug-likeness evaluation, blood-brain barrier permeation, target identification and network analysis	[111]
<i>Semen strychni</i> and <i>Tripterygium wilfordii</i> Hook F.	Data mining, target prediction, network analysis	[144]
<i>Sinomenium acutum</i>	Pathway, network and function analyses, data mining	[145]
Anti-Thrombosis Drug from TCMs	Data mining, molecular docking, <i>in silico</i> screening	[146]
Qi-enriching herbs and blood-tonifying herbs	ADME prediction, target fishing and network analysis	[147]
Baihe Dihuang Tang	ADME/T calculation, target prediction, network analysis	[148]
Bufei Jianpi formula	Systems pharmacology modeling based on absorption filtering, network targeting and systems analyses	[132,149]
Bushenhuoxue formula	Target screening, molecular docking, network analysis, literature mining	[150]
Bushen-Yizhi prescription	ADME/T filter analysis, target prediction, network analysis	[151]
Danlu Capsules	Oral bioavailability and drug-likeness evaluation, gene enrichment analysis	[152]
Danggui-shaoyao-san	Oral bioavailability screening, drug-likeness assessment, target identification and network analysis	[153]
Diesun Miaofang	Cluster ligands, human intestinal absorption and aqueous solution prediction, chemical space mapping, molecular docking and network pharmacology techniques	[154]
Dragon's blood tablets	Chemical analysis, prediction of ADME, and network analysis	[155]
Ge-Gen-Qin-Lian decoction	Target profile clustering, network target analysis	[156]
Liu-Wei-Di-Huang pill	Chemical and therapeutic properties, network analysis	[157]
Ma-huang decoction	Pharmacokinetic analysis, drug targeting, and drug-target-disease network analysis	[158]
Mahuang Fuzi Xixin decoction	Drug-likeness evaluation, oral bioavailability prediction, multiple drug target prediction, and network analysis	[159]
MaZiRenWan	UPLC-QTOF-MS/MS identification, hierarchical clustering analysis, <i>in vitro</i> experiment verification, network analysis	[160]
NiaoDuQing granules	ADME modelling and target prediction, topology analysis, pathway enrichment analysis, rat test	[161]
Qigui Tongfeng tablet	Molecular similarity analysis, network analysis	[162]
Radix Curcumae formula	Chemical predictors based on chemical structure and chemogenomics data linking compounds, pharmacological information, a system biology functional data analysis and network reconstruction method	[163]
Reduning injection	ADME filtering, network targeting, pathways integrating, target selection, reverse drug targeting and network analysis	[164–166]
Shenmai injection	Network construction, network recovery index evaluation	[167]
SiNiSan formula	ADME screening, targets prediction, and DAVID enrichment analysis,	[168,169]
Taohong Siwu decoction	Chemical space analysis, virtual screening, chemical distribution and potential compound prediction	[170]
Tian-Ma-Gou-Teng-Yin fomula	Network link prediction and statistical analysis	[171]
Tianshu formula	Pharmacokinetic filtering, target fishing and network analysis	[172]
Xiaoyaosan	Reversed pharmacophore matching method, network analysis	[173]
Xijiao Dihuang decoction	ADME screening, drug targeting, network and pathway analysis	[174]

(Continued)

TCM	Computational method	Refs.
Xin-Sheng-Hua granule	Plasma metabolomics profiling with UHPLC-QTOF/MS and multivariate data method, network analysis	[175]
Xing-Nao-Jing	Drug-likeness and brain-blood-barrier evaluation, biological process and pathway enrichment analyses	[130]
Yangxinshi tablet	Molecular docking, network analysis	[176]
Yinchenhao decoction	Oral bioavailability screening, drug-likeness and intestinal epithelial permeability evaluation, target prediction, pathway identification and network construction	[177]
Zhi-Zi-Da-Huang decoction	Molecular docking and network analysis	[178]
Ginsenoside Rb1, ginsenoside Rg1, schizandrin and DT-13 (effective compounds from ShengMai preparations)	Target-pathway network analysis	[179]

and systems analysis and identified 145 bioactive ingredients and 175 potential targets [149]. The model also provides insights of potential synergistic effects between herbs which links with similar targets. Wang *et al.* used a systems pharmacology method to provide new insights into the pharmacological interactions of *Ophiocordyceps sinensis* so as to find new adjuvant for hepatitis B vaccine [182]. Yang *et al.* built an *in silico* model to predict potential P-Glycoprotein inhibitors and select out 875 potential P-Glycoprotein inhibitors and 15 inhibitor-rich herbs from TCMSP [75]. These results make TCM more reasonable and promote the modernization of TCM.

FUTURE PROSPECT

QSP integrates various types of *in vivo* and *in vitro* results from different research areas. QSP methods can simulate a series of biological processes and diseases for multiple-scale and systematic exploration of MoA of drugs. The biological responses and changes in disease treatments from the molecular and genetic level to systems level provide a deep insight into these processes. It can also make up quantitative and credible predictions for complex disease while the pathogenesis is not yet fully understood. There are still many challenges in both developing QSP methods and applications. The lack of biological and pharmacological details for complex disease leads to deviations in simulations. Analytical and comprehensive multi-level evaluation methods are urgently needed to construct the appropriate models. Complex associations between factors involved in MoA of drugs further increase the difficulty to obtain meaningful results by analyzing the predictions of modeling. With the development of omics technologies and mathematical techniques such as network dynamics, ordinary differential equations, logic-based approaches, statistical regression and finite element methods, QSP will

help to understand the MoA of drugs and TCM, and to improve the efficiency of drug discovery.

ACKNOWLEDGEMENTS

This work was supported by the start-up support for scientific research of Xinglin Young Scholar in Guangzhou University of Chinese Medicine (A1-AFD018161Z04).

COMPLIANCE WITH ETHICAL GUIDELINES

Fuda Xie and Jiangyong Gu declare that they have no conflict of interests.

This article is a review article and does not contain any studies with human or animal subjects performed by any of the authors.

REFERENCES

- Berger, S. I. and Iyengar, R. (2009) Network analyses in systems pharmacology. *Bioinformatics*, 25, 2466–2472
- Zhao, S. and Iyengar, R. (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. *Annu. Rev. Pharmacol. Toxicol.*, 52, 505–521
- Boran, A. D. and Iyengar, R. (2010) Systems pharmacology. *Mt. Sinai J. Med.*, 77, 333–344
- Zhou, W., Wang, Y., Lu, A. and Zhang, G. (2016) Systems pharmacology in small molecular drug discovery. *Int. J. Mol. Sci.*, 17, 246
- Gu, J., Zhang, X., Ma, Y., Li, N., Luo, F., Cao, L., Wang, Z., Yuan, G., Chen, L., Xiao, W., *et al.* (2015) Quantitative modeling of dose-response and drug combination based on pathway network. *J. Cheminform.*, 7, 19
- Spiros, A., Roberts, P. and Geerts, H. (2014) A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance. *Front. Pharmacol.*, 5, 229
- Fang, J., Wu, Z., Cai, C., Wang, Q., Tang, Y. and Cheng, F. (2017) Quantitative and systems pharmacology. 1. *in silico* prediction of drug-target interactions of natural products enables new targeted

- cancer therapy. *J. Chem. Inf. Model.*, 57, 2657–2671
8. Fleisher, B., Brown, A. N. and Ait-Oudhia, S. (2017) Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: the example of luminal a breast cancer. *Pharmacol. Res.*, 124, 20–33
 9. Geerts, H., Spiros, A. and Roberts, P. (2018) Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model. *Alzheimers Res. Ther.*, 10, 14
 10. Barabási, A. L., Gulbahce, N. and Loscalzo, J. (2011) Network medicine: a network-based approach to human disease. *Nat. Rev. Genet.*, 12, 56–68
 11. Pérez-Nueno, V. I. (2015) Using quantitative systems pharmacology for novel drug discovery. *Expert Opin. Drug Discov.*, 10, 1315–1331
 12. Woodhead, J. L., Watkins, P. B., Howell, B. A., Siler, S. Q. and Shoda, L. K. M. (2017) The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. *Drug Metab. Pharmacokinet.*, 32, 40–45
 13. Androulakis, I. P. (2016) Quantitative systems pharmacology: a framework for context. *Curr. Pharmacol. Rep.*, 2, 152–160
 14. van der Graaf, P. H. and Benson, N. (2011) Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. *Pharm. Res.*, 28, 1460–1464
 15. Leil, T. A. and Bertz, R. (2014) Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. *Front. Pharmacol.*, 5, 247
 16. Rao, R. T., Scherholz, M. L., Hartmanshenn, C., Bae, S. A. and Androulakis, I. P. (2017) On the analysis of complex biological supply chains: from process systems engineering to quantitative systems pharmacology. *Comput. Chem. Eng.*, 107, 100–110
 17. Yu, J., Cilfone, N. A., Large, E. M., Sarkar, U., Wishnok, J. S., Tannenbaum, S. R., Hughes, D. J., Lauffenburger, D. A., Griffith, L. G., Stokes, C. L., *et al.* (2015) Quantitative systems pharmacology approaches applied to microphysiological systems (MPS): data interpretation and multi-MPS integration. *CPT Pharmacometrics Syst. Pharmacol.*, 4, 585–594
 18. Musante, C. J., Abernethy, D. R., Allerheiligen, S. R., Lauffenburger, D. A. and Zager, M. G. (2016) GPS for QSP: A summary of the ACoP6 symposium on quantitative systems pharmacology and a stage for near-term efforts in the field. *CPT Pharmacometrics Syst. Pharmacol.*, 5, 449–451
 19. Ribba, B., Grimm, H. P., Agoram, B., Davies, M. R., Gadkar, K., Niederer, S., van Riel, N., Timmis, J. and van der Graaf, P. H. (2017) Methodologies for quantitative systems pharmacology (QSP) models: design and estimation. *CPT Pharmacometrics Syst. Pharmacol.*, 6, 496–498
 20. Timmis, J., Alden, K., Andrews, P., Clark, E., Nellis, A., Naylor, B., Coles, M. and Kaye, P. (2017) Building confidence in quantitative systems pharmacology models: an engineer's guide to exploring the rationale in model design and development. *CPT Pharmacometrics Syst. Pharmacol.*, 6, 156–167
 21. Cherkaoui-Rbati, M. H., Paine, S. W., Littlewood, P. and Rauch, C. (2017) A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions. *PLoS One*, 12, e0183794
 22. Rogers, M., Lyster, P. and Okita, R. (2013) NIH support for the emergence of quantitative and systems pharmacology. *CPT Pharmacometrics Syst. Pharmacol.*, 2, e37
 23. Wist, A. D., Berger, S. I. and Iyengar, R. (2009) Systems pharmacology and genome medicine: a future perspective. *Genome Med.*, 1, 11
 24. Wang, Z. and Deisboeck, T. S. (2014) Mathematical modeling in cancer drug discovery. *Drug Discov. Today*, 19, 145–150
 25. Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S. and Houghten, R. A. (2013) Shifting from the single to the multitarget paradigm in drug discovery. *Drug Discov. Today*, 18, 495–501
 26. Hopkins, A. L. (2007) Network pharmacology. *Nat. Biotechnol.*, 25, 1110–1111
 27. Goh, K. I. and Choi, I. G. (2012) Exploring the human diseasesome: the human disease network. *Brief. Funct. Genomics*, 11, 533–542
 28. Goh, K. I., Cusick, M. E., Valle, D., Childs, B., Vidal, M. and Barabási, A. L. (2007) The human disease network. *Proc. Natl. Acad. Sci. USA*, 104, 8685–8690
 29. Zhang, W., Pei, J. and Lai, L. (2017) Computational multitarget drug design. *J. Chem. Inf. Model.*, 57, 403–412
 30. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabási, A. L. and Vidal, M. (2007) Drug-target network. *Nat. Biotechnol.*, 25, 1119–1126
 31. Barneh, F., Jafari, M. and Mirzaie, M. (2016) Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database. *Brief. Bioinformatics*, 17, 1070–1080
 32. Geerts, H., Spiros, A., Roberts, P. and Carr, R. (2013) Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development. *J. Pharmacokinet. Pharmacodyn.*, 40, 257–265
 33. Snelder, N., Ploeger, B. A., Luttringer, O., Rigel, D. F., Fu, F., Beil, M., Stanski, D. R. and Danhof, M. (2014) Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling. *Br. J. Pharmacol.*, 171, 5076–5092
 34. Hansson, E. K., Amantea, M. A., Westwood, P., Milligan, P. A., Houk, B. E., French, J., Karlsson, M. O. and Friberg, L. E. (2013) PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST. *CPT Pharmacometrics Syst. Pharmacol.*, 2, e84
 35. Reymond, J. L. and Awale, M. (2012) Exploring chemical space for drug discovery using the chemical universe database. *ACS Chem. Neurosci.*, 3, 649–657
 36. Tian, S., Wang, J., Li, Y., Li, D., Xu, L. and Hou, T. (2015) The application of *in silico* drug-likeness predictions in pharmaceutical research. *Adv. Drug Deliv. Rev.*, 86, 2–10
 37. May, E. R. (2014) Recent developments in molecular simulation

- approaches to study spherical virus capsids. *Mol. Simul.*, 40, 878–888
38. Field, M. J. (2015) Technical advances in molecular simulation since the 1980s. *Arch. Biochem. Biophys.*, 582, 3–9
 39. Xie, L., Draizen, E. J. and Bourne, P. E. (2017) Harnessing big data for systems pharmacology. *Annu. Rev. Pharmacol. Toxicol.*, 57, 245–262
 40. Liu, X., Zhu, F., Ma, X. H., Shi, Z., Yang, S. Y., Wei, Y. Q. and Chen, Y. Z. (2013) Predicting targeted polypharmacology for drug repositioning and multi-target drug discovery. *Curr. Med. Chem.*, 20, 1646–1661
 41. Chiu, S. H. and Xie, L. (2016) Toward high-throughput predictive modeling of protein binding/unbinding kinetics. *J. Chem. Inf. Model.*, 56, 1164–1174
 42. Hart, T. and Xie, L. (2016) Providing data science support for systems pharmacology and its implications to drug discovery. *Expert Opin. Drug Discov.*, 11, 241–256
 43. Bloomingdale, P., Nguyen, V. A., Niu, J. and Mager, D. E. (2018) Boolean network modeling in systems pharmacology. *J. Pharmacokinet. Pharmacodyn.*, 45, 159–180
 44. Irurzun-Arana, I., Pastor, J. M., Trocóniz, I. F. and Gómez-Mantilla, J. D. (2017) Advanced Boolean modeling of biological networks applied to systems pharmacology. *Bioinformatics*, 33, 1040–1048
 45. Danhof, M. (2016) Systems pharmacology—towards the modeling of network interactions. *Eur. J. Pharm. Sci.*, 94, 4–14
 46. Tang, Y., Tang, Q., Dong, C., Li, X., Zhang, Z. and An, F. (2015) Protein-protein interaction network and mechanism analysis of hepatitis C. *Genet. Mol. Res.*, 14, 2069–2079
 47. Schurdak, M. E., Pei, F., Lezon, T. R., Carlisle, D., Friedlander, R., Taylor, D. L. and Stern, A. M. (2018) A quantitative systems pharmacology approach to infer pathways involved in complex disease phenotypes. *Methods Mol. Biol.*, 1787, 207–222
 48. Li, Q., Li, X., Li, C., Chen, L., Song, J., Tang, Y. and Xu, X. (2011) A network-based multi-target computational estimation scheme for anticoagulant activities of compounds. *PLoS One*, 6, e14774
 49. Zhang, X., Gu, J., Cao, L., Ma, Y., Su, Z., Luo, F., Wang, Z., Li, N., Yuan, G., Chen, L., *et al.* (2014) Insights into the inhibition and mechanism of compounds against LPS-induced PGE2 production: a pathway network-based approach and molecular dynamics simulations. *Integr. Biol.*, 6, 1162–1169
 50. Gu, J., Li, Q., Chen, L., Li, Y., Hou, T., Yuan, G. and Xu, X. (2013) Platelet aggregation pathway network-based approach for evaluating compounds efficacy. *Evid. Based Complement. Alternat. Med.*, 2013, 425707
 51. Traynard, P., Tobalina, L., Eduati, F., Calzone, L. and Saez-Rodriguez, J. (2017) Logic modeling in quantitative systems pharmacology. *CPT Pharmacometrics Syst. Pharmacol.*, 6, 499–511
 52. Ru, J., Li, P., Wang, J., Zhou, W., Li, B., Huang, C., Li, P., Guo, Z., Tao, W., Yang, Y., *et al.* (2014) TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. *J. Cheminform.*, 6, 13
 53. Chassagnole, C., Jackson, R. C., Hussain, N., Bashir, L., Derow, C., Savin, J. and Fell, D. A. (2006) Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. *Biosystems*, 83, 91–97
 54. Tao, W., Li, B., Gao, S., Bai, Y., Shar, P. A., Zhang, W., Guo, Z., Sun, K., Fu, Y., Huang, C., *et al.* (2015) CancerHSP: anticancer herbs database of systems pharmacology. *Sci. Rep.*, 5, 11481
 55. Huang, H., Wu, X., Pandey, R., Li, J., Zhao, G., Ibrahim, S. and Chen, J. Y. (2012) C²Maps: a network pharmacology database with comprehensive disease-gene-drug connectivity relationships. *BMC Genomics*, 13, S17
 56. Hu, Z., Chang, Y. C., Wang, Y., Huang, C. L., Liu, Y., Tian, F., Granger, B. and Delisi, C. (2013) VisANT 4.0: integrative network platform to connect genes, drugs, diseases and therapies. *Nucleic Acids Res.*, 41, W225–W 231
 57. Wang, D., Gu, J., Zhu, W., Luo, F., Chen, L., Xu, X. and Lu, C. (2017) PDTCM: a systems pharmacology platform of traditional Chinese medicine for psoriasis. *Ann. Med.*, 49, 652–660
 58. Gu, J., Gui, Y., Chen, L., Yuan, G. and Xu, X. (2013) CVDHD: a cardiovascular disease herbal database for drug discovery and network pharmacology. *J. Cheminform.*, 5, 51
 59. Musante, C. J., Ramanujan, S., Schmidt, B. J., Ghobrial, O. G., Lu, J. and Heatherington, A. C. (2017) Quantitative systems pharmacology: a case for disease models. *Clin. Pharmacol. Ther.*, 101, 24–27
 60. Schmidt, B. J., Casey, F. P., Paterson, T. and Chan, J. R. (2013) Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis. *BMC Bioinformatics*, 14, 221
 61. Ghosh, S., Matsuoka, Y., Asai, Y., Hsin, K. Y. and Kitano, H. (2013) Toward an integrated software platform for systems pharmacology. *Biopharm. Drug Dispos.*, 34, 508–526
 62. Spiros, A., Roberts, P. and Geerts, H. (2013) Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform. *J Parkinsons Dis*, 3, 569–580
 63. Ming, J. E., Abrams, R. E., Bartlett, D. W., Tao, M., Nguyen, T., Surks, H., Kudrycki, K., Kadambi, A., Friedrich, C. M., Djebli, N., *et al.* (2017) A quantitative systems pharmacology platform to investigate the impact of alirocumab and cholesterol-lowering therapies on lipid profiles and plaque characteristics. *Gene Regul. Syst. Bio.*, 11, 1177625017710941
 64. Zheng, C., Pei, T., Huang, C., Chen, X., Bai, Y., Xue, J., Wu, Z., Mu, J., Li, Y. and Wang, Y. (2016) A novel systems pharmacology platform to dissect action mechanisms of traditional Chinese medicines for bovine viral diarrhea disease. *Eur. J. Pharm. Sci.*, 94, 33–45
 65. Rieger, T. R., Allen, R. J., Bystricky, L., Chen, Y., Colopy, G. W., Cui, Y., Gonzalez, A., Liu, Y., White, R. D., Everett, R. A., *et al.* (2018) Improving the generation and selection of virtual populations in quantitative systems pharmacology models. *Prog. Biophys. Mol. Biol.*, 139, 15–22
 66. Geerts, H., Spiros, A., Roberts, P. and Carr, R. (2017) Towards the virtual human patient. *quantitative systems pharmacology in*

- Alzheimer's disease. *Eur. J. Pharmacol.*, 817, 38–45
67. Wiśniowska, B. and Polak, S. (2016) Virtual clinical trial toward polytherapy safety assessment: combination of physiologically based pharmacokinetic/pharmacodynamic-based modeling and simulation approach with drug-drug interactions involving terfenadine as an example. *J. Pharm. Sci.*, 105, 3415–3424
 68. Allen, R. J., Rieger, T. R. and Musante, C. J. (2016) Efficient generation and selection of virtual populations in quantitative systems pharmacology models. *CPT Pharmacometrics Syst. Pharmacol.*, 5, 140–146
 69. Rostami-Hodjegan, A. (2012) Physiologically based pharmacokinetics joined with *in vitro*–*in vivo* extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clin. Pharmacol. Ther.*, 92, 50–61
 70. Bloomingdale, P., Housand, C., Apgar, J. F., Millard, B. L., Mager, D. E., Burke, J. M. and Shah, D. K. (2017) Quantitative systems toxicology. *Curr. Opin. Toxicol.*, 4, 79–87
 71. Pichardo-Almarza, C. and Diaz-Zuccarini, V. (2017) From PK/PD to QSP: understanding the dynamic effect of cholesterol-lowering drugs on atherosclerosis progression and stratified medicine. *Curr. Pharm. Des.*, 22, 6903–6910
 72. Meng, X. Y., Zhang, H. X., Mezei, M. and Cui, M. (2011) Molecular docking: a powerful approach for structure-based drug discovery. *Curr. Comput. Aided Drug Des.*, 7, 146–157
 73. Omer, A. and Singh, P. (2017) An integrated approach of network-based systems biology, molecular docking, and molecular dynamics approach to unravel the role of existing antiviral molecules against AIDS-associated cancer. *J. Biomol. Struct. Dyn.*, 35, 1547–1558
 74. Gu, J., Li, L., Wang, D., Zhu, W., Han, L., Zhao, R., Xu, X. and Lu, C. (2018) Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology. *Ann. Med.*, 50, 323–332
 75. Yang, M., Chen, J., Shi, X., Xu, L., Xi, Z., You, L., An, R. and Wang, X. (2015) Development of *in silico* models for predicting p-glycoprotein inhibitors based on a two-step approach for feature selection and its application to Chinese herbal medicine screening. *Mol. Pharm.*, 12, 3691–3713
 76. Gilson, M. K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L. and Chong, J. (2016) BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. *Nucleic Acids Res.*, 44, D1045–D1053
 77. Liu, Z., Guo, F., Wang, Y., Li, C., Zhang, X., Li, H., Diao, L., Gu, J., Wang, W., Li, D., *et al.* (2016) BATMAN-TCM: a bioinformatics analysis Tool for molecular mechanism of traditional Chinese medicine. *Sci. Rep.*, 6, 21146
 78. Boran, A. D. and Iyengar, R. (2010) Systems approaches to polypharmacology and drug discovery. *Curr Opin Drug Discov Devel*, 13, 297–309
 79. Berger, S. I., Ma'ayan, A. and Iyengar, R. (2010) Systems pharmacology of arrhythmias. *Sci. Signal.*, 3, ra30
 80. Boland, M. R., Jacunski, A., Lorberbaum, T., Romano, J. D., Moskovitch, R. and Tatonetti, N. P. (2016) Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms. *Wiley Interdiscip. Rev. Syst. Biol. Med.*, 8, 104–122
 81. Goldstein, L. H., Berlin, M., Saliba, W., Elias, M. and Berkovitch, M. (2013) Founding an adverse drug reaction (ADR) network: a method for improving doctors spontaneous ADR reporting in a general hospital. *J. Clin. Pharmacol.*, 53, 1220–1225
 82. Zhao, S., Nishimura, T., Chen, Y., Azeloglu, E. U., Gottesman, O., Giannarelli, C., Zafar, M. U., Benard, L., Badimon, J. J., Hajjar, R. J., *et al.* (2013) Systems pharmacology of adverse event mitigation by drug combinations. *Sci. Transl. Med.*, 5, 206ra140
 83. Wu, Z., Cheng, F., Li, J., Li, W., Liu, G. and Tang, Y. (2017) SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning. *Brief. Bioinformatics*, 18, 333–347
 84. Wu, Z., Lu, W., Wu, D., Luo, A., Bian, H., Li, J., Li, W., Liu, G., Huang, J., Cheng, F., *et al.* (2016) *In silico* prediction of chemical mechanism of action via an improved network-based inference method. *Br. J. Pharmacol.*, 173, 3372–3385
 85. Wang, J., Guo, Z., Fu, Y., Wu, Z., Huang, C., Zheng, C., Shar, P. A., Wang, Z., Xiao, W. and Wang, Y. (2017) Weak-binding molecules are not drugs?—toward a systematic strategy for finding effective weak-binding drugs. *Brief. Bioinformatics*, 18, 321–332
 86. Huang, C., Zheng, C., Li, Y., Wang, Y., Lu, A. and Yang, L. (2014) Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. *Brief. Bioinform.*, 15, 710–733
 87. Mitrea, C., Taghavi, Z., Bokanizad, B., Hanoudi, S., Tagett, R., Donato, M., Voichița, C. and Drăghici, S. (2013) Methods and approaches in the topology-based analysis of biological pathways. *Front. Physiol.*, 4, 278
 88. Nie, X. Z., Du, X., Zhang, R. R., He, J., Su, R., Ma, H. Q., Mu, J., Li, Y. and Liu, F. (2017) Study on regulation mechanism of Toutongning capsule through TNF signaling pathway in treatment of migraine based on systems pharmacology method. *Zhongguo Zhongyao Zazhi*, 42, 548–554, in Chinese
 89. Gu, J., Crosier, P. S., Hall, C. J., Chen, L. and Xu, X. (2016) Inflammatory pathway network-based drug repositioning and molecular phenomics. *Mol. Biosyst.*, 12, 2777–2784
 90. Poltz, R. and Naumann, M. (2012) Dynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention. *BMC Syst. Biol.*, 6, 125
 91. Le Novère, N. (2015) Quantitative and logic modelling of molecular and gene networks. *Nat. Rev. Genet.*, 16, 146–158
 92. Chaouiya, C. and Remy, E. (2013) Logical modelling of regulatory networks, methods and applications. *Bull. Math. Biol.*, 75, 891–895
 93. Kirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R., Yazar, D., Paragas, V., Pace, E., McDonagh, C. F., Nielsen, U. B. and Onsum, M. D. (2013) Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. *Sci. Signal.*, 6, ra68
 94. Shoda, L. K., Woodhead, J. L., Siler, S. Q., Watkins, P. B. and

- Howell, B. A. (2014) Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. *Biopharm. Drug Dispos.*, 35, 33–49
95. Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L., Barton, H. A. and Howell, B. A. (2014) Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. *Front. Pharmacol.*, 5, 240
 96. Woodhead, J. L., Paech, F., Maurer, M., Engelhardt, M., Schmitt-Hoffmann, A. H., Spickermann, J., Messner, S., Wind, M., Witschi, A. T., Krähenbühl, S., *et al.* (2018) Prediction of safety margin and optimization of dosing protocol for a novel antibiotic using quantitative systems pharmacology modeling. *Clin. Transl. Sci.*, 11, 498–505
 97. Geerts, H., Roberts, P. and Spiros, A. (2015) Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. *Front. Pharmacol.*, 6, 198
 98. Hopkins, A. L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat. Chem. Biol.*, 4, 682–690
 99. Allerheiligen, S. R. (2010) Next-generation model-based drug discovery and development: quantitative and systems pharmacology. *Clin. Pharmacol. Ther.*, 88, 135–137
 100. Agoram, B. M. and Demin, O. (2011) Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. *Drug Discov. Today*, 16, 1031–1036
 101. Geerts, H. and Kennis, L. (2014) Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward. *Future Med. Chem.*, 6, 1757–1769
 102. Fang, J., Gao, L., Ma, H., Wu, Q., Wu, T., Wu, J., Wang, Q. and Cheng, F. (2017) Quantitative and systems pharmacology 3. network-based identification of new targets for natural products enables potential uses in aging-associated disorders. *Front. Pharmacol.*, 8, 747
 103. Janga, S. C. and Tzacos, A. (2009) Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. *Mol. Biosyst.*, 5, 1536–1548
 104. Arrell, D. K. and Terzic, A. (2010) Network systems biology for drug discovery. *Clin. Pharmacol. Ther.*, 88, 120–125
 105. Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L. and Le Novère, N. (2016) The promises of quantitative systems pharmacology modelling for drug development. *Comput. Struct. Biotechnol. J.*, 14, 363–370.
 106. Kim, S., Lahu, G., Lesko, L. J. and Trame, M. N. (2017) An exemplar of a systems pharmacology approach for a detailed investigation of an adverse drug event as a result of drug-drug interactions. *Clin. Pharmacol. Ther.*, 101, S97–S97.
 107. Kariya, Y., Honma, M. and Suzuki, H. (2016) Mechanism analyses and mechanism-based prediction for adverse drug reactions using systems pharmacology. *Nippon Yakurigaku Zasshi*, 147, 89–94, in Japanese
 108. Cao, D. S., Xiao, N., Li, Y. J., Zeng, W. B., Liang, Y. Z., Lu, A. P., Xu, Q. S. and Chen, A. F. (2015) Integrating multiple evidence sources to predict adverse drug reactions based on a systems pharmacology model. *CPT Pharmacometrics Syst. Pharmacol.*, 4, 498–506
 109. Berger, S. I. and Iyengar, R. (2011) Role of systems pharmacology in understanding drug adverse events. *Wiley Interdiscip. Rev. Syst. Biol. Med.*, 3, 129–135
 110. Nueno, V. I. (2016) Towards the integration of quantitative and systems pharmacology into drug discovery: a systems level understanding of therapeutic and toxic effects of drugs. *Curr. Pharm. Des.*, 22, 6881–6884
 111. Liu, H., Wang, J., Zhou, W., Wang, Y. and Yang, L. (2013) Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. *J. Ethnopharmacol.*, 146, 773–793
 112. Luo, F., Gu, J., Chen, L. and Xu, X. (2014) Systems pharmacology strategies for anticancer drug discovery based on natural products. *Mol. Biosyst.*, 10, 1912–1917
 113. Dziuba, J., Alperin, P., Racketa, J., Iloeje, U., Goswami, D., Hardy, E., Perlstein, I., Grossman, H. L. and Cohen, M. (2014) Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. *Diabetes Obes. Metab.*, 16, 628–635
 114. Peskin, B. R., Shcheprov, A. V., Boye, K. S., Bruce, S., Maggs, D. G. and Gaebler, J. A. (2011) Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. *Diabetes Obes. Metab.*, 13, 921–927
 115. Gadkar, K., Kirouac, D., Parrott, N. and Ramanujan, S. (2016) Quantitative systems pharmacology: a promising approach for translational pharmacology. *Drug Discov. Today. Technol.*, 21–22, 57–65
 116. Cirit, M. and Stokes, C. L. (2018) Maximizing the impact of microphysiological systems with *in vitro-in vivo* translation. *Lab Chip*, 18, 1831–1837
 117. Yuraszeck, T., Kasichayanula, S. and Benjamin, J. E. (2017) Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. *Clin. Pharmacol. Ther.*, 101, 634–645
 118. Schulthess, P., Post, T. M., Yates, J. and van der Graaf, P. H. (2018) Frequency-domain response analysis for quantitative systems pharmacology models. *CPT Pharmacometrics Syst. Pharmacol.*, 7, 111–123
 119. Visser, S. A., de Alwis, D. P., Kerbusch, T., Stone, J. A. and Allerheiligen, S. R. (2014) Implementation of quantitative and systems pharmacology in large pharma. *CPT Pharmacometrics Syst. Pharmacol.*, 3, e142
 120. Geerts, H., Roberts, P. and Spiros, A. (2013) A quantitative system pharmacology computer model for cognitive deficits in schizophrenia. *CPT Pharmacometrics Syst. Pharmacol.*, 2, e36
 121. Liu, J., Ogden, A., Comery, T. A., Spiros, A., Roberts, P. and Geerts, H. (2014) Prediction of efficacy of vabicaserin, a 5-HT_{2C} agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. *CPT Pharmacometrics Syst. Pharmacol.*, 3, e111

122. Geerts, H., Roberts, P., Spiros, A. and Potkin, S. (2015) Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone. *J. Psychopharmacol. (Oxford)*, 29, 372–382
123. Vega-Villa, K., Pluta, R., Lonser, R. and Woo, S. (2013) Quantitative systems pharmacology model of NO metabolome and methemoglobin following long-term infusion of sodium nitrite in humans. *CPT Pharmacometrics Syst. Pharmacol.*, 2, e60
124. John, T., Kiss, T., Lever, C. and Érdi, P. (2014) Anxiolytic drugs and altered hippocampal theta rhythms: the quantitative systems pharmacological approach. *Network*, 25, 20–37
125. Johnson, T. N. and Rostami-Hodjegan, A. (2011) Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. *Paediatr. Anaesth.*, 21, 291–301
126. Kaddi, C. D., Niesner, B., Baek, R., Jasper, P., Pappas, J., Tolsma, J., Li, J., van Rijn, Z., Tao, M., Ortemann-Renon, C., *et al.* (2018) Quantitative systems pharmacology modeling of acid sphingomyelinase deficiency and the enzyme replacement therapy olipudase alfa is an innovative tool for linking pathophysiology and pharmacology. *CPT Pharmacometrics Syst. Pharmacol.*, 7, 442–452
127. Stern, A. M., Schurdak, M. E., Bahar, I., Berg, J. M. and Taylor, D. L. (2016) A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine. *J. Biomol. Screen.*, 21, 521–534
128. Geerts, H., Spiros, A., Roberts, P. and Alphs, L. (2018) A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly. *Schizophr. Res.*, 197, 261–268
129. Yin, A., Yamada, A., Stam, W. B., van Hasselt, J. G. C. and van der Graaf, P. H. (2018) Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction. *Br. J. Pharmacol.*, 175, 3394–3406
130. Chen, Y., Sun, Y., Li, W., Wei, H., Long, T., Li, H., Xu, Q. and Liu, W. (2018) Systems pharmacology dissection of the anti-stroke mechanism for the Chinese traditional medicine Xing-Nao-Jing. *J. Pharmacol. Sci.*, 136, 16–25
131. Li, J., Zhao, P., Li, Y., Tian, Y. and Wang, Y. (2015) Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. *Sci. Rep.*, 5, 15290
132. Zhao, P., Yang, L., Li, J., Li, Y., Tian, Y. and Li, S. (2016) Combining systems pharmacology, transcriptomics, proteomics, and metabolomics to dissect the therapeutic mechanism of Chinese herbal Bufei Jianpi formula for application to COPD. *Int. J. Chron. Obstruct. Pulmon. Dis.*, 11, 553–566
133. Zhao, P., Li, J., Yang, L., Li, Y., Tian, Y. and Li, S. (2018) Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease. *Mol. Med. Rep.*, 17, 5247–5257
134. Zhang, W., Tao, Q., Guo, Z., Fu, Y., Chen, X., Shar, P. A., Shahan, M., Zhu, J., Xue, J., Bai, Y., *et al.* (2016) Systems pharmacology dissection of the integrated treatment for cardiovascular and gastrointestinal disorders by traditional Chinese medicine. *Sci. Rep.*, 6, 32400
135. Sun, M., Chang, W. T., Van Wijk, E., He, M., Koval, S., Lin, M. K., Van Wijk, R., Hankemeier, T., van der Greef, J. and Wang, M. (2017) Characterization of the therapeutic properties of Chinese herbal materials by measuring delayed luminescence and dendritic cell-based immunomodulatory response. *J. Photochem. Photobiol. B*, 168, 1–11
136. Wang, J., Li, Y., Yang, Y., Chen, X., Du, J., Zheng, Q., Liang, Z. and Wang, Y. (2017) A new strategy for deleting animal drugs from traditional Chinese medicines based on modified yimusake formula. *Sci. Rep.*, 7, 1504
137. Ai, H., Wu, X., Qi, M., Zhang, L., Hu, H., Zhao, Q., Zhao, J. and Liu, H. (2018) Study on the mechanisms of active compounds in traditional Chinese medicine for the treatment of influenza virus by virtual screening. *Interdiscip. Sci.*, 10, 320–328
138. Jiang, Q. Y., Zheng, M. S., Yang, X. J. and Sun, X. S. (2016) Analysis of molecular networks and targets mining of Chinese herbal medicines on anti-aging. *BMC Complement. Altern. Med.*, 16, 520
139. Liu, J., Liu, J., Shen, F., Qin, Z., Jiang, M., Zhu, J., Wang, Z., Zhou, J., Fu, Y., Chen, X., *et al.* (2018) Systems pharmacology analysis of synergy of TCM: an example using saffron formula. *Sci. Rep.*, 8, 380
140. Fan, W. T. and Wang, Q. (2018) Mechanism of Acori Tatarinowii Rhizoma-Curcumae Radix treating depression based on network pharmacology. *Zhongguo Zhongyao Zazhi*, 43, 2607–2611, in Chinese
141. Wang, J., Zhang, L., Liu, B., Wang, Q., Chen, Y., Wang, Z., Zhou, J., Xiao, W., Zheng, C. and Wang, Y. (2018) Systematic investigation of the Erigeron breviscapus mechanism for treating cerebrovascular disease. *J. Ethnopharmacol.*, 224, 429–440
142. Li, Y., Han, C., Wang, J., Xiao, W., Wang, Z., Zhang, J., Yang, Y., Zhang, S. and Ai, C. (2014) Investigation into the mechanism of *Eucommia ulmoides* Oliv. based on a systems pharmacology approach. *J. Ethnopharmacol.*, 151, 452–460
143. Liu, X., Wu, J., Zhang, D., Wang, K., Duan, X. and Zhang, X. (2018) A network pharmacology approach to uncover the multiple mechanisms of *Hedyotis diffusa* Willd. on colorectal cancer. *Evid. Based Complement. Alternat. Med.*, 2018, 6517034
144. Li, Y., Wang, J., Xiao, Y., Wang, Y., Chen, S., Yang, Y., Lu, A. and Zhang, S. (2015) A systems pharmacology approach to investigate the mechanisms of action of semen strychni and *Tripterygium wilfordii* Hook F for treatment of rheumatoid arthritis. *J. Ethnopharmacol.*, 175, 301–314
145. Li, Y. Y., Zheng, G. and Liu, L. (2018) Bioinformatics based therapeutic effects of *Sinomenium Acutum*. *Chin. J. Integr. Med.*, 10.1007/s11655-018-2796-6

146. Yi, F., Sun, L., Xu, L. J., Peng, Y., Liu, H. B., He, C. N. and Xiao, P. G. (2017) *In silico* approach for anti-thrombosis drug discovery: P2Y₁R structure-based TCMs screening. *Front. Pharmacol.*, 7, 531
147. Liu, J., Pei, M., Zheng, C., Li, Y., Wang, Y., Lu, A. and Yang, L. (2013) A systems-pharmacology analysis of herbal medicines used in health improvement treatment: predicting potential new drugs and targets. *Evid. Based Complement. Alternat. Med.*, 2013, 938764
148. Zhao, L., Wu, Y. F., Gao, Y., Xiang, H., Qin, X. M. and Tian, J. S. (2017) Intervention mechanism of psychological sub-health by Baihe Dihuang Tang based on network pharmacology. *Acta Pharma. Sinica* (Yao Xue Xue Bao), 52, 99–105, in Chinese
149. Zhao, P., Li, J., Li, Y., Tian, Y., Wang, Y. and Zheng, C. (2015) Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD. *Int. J. Chron. Obstruct. Pulmon. Dis.*, 10, 2633–2656
150. Shi, S. H., Cai, Y. P., Cai, X. J., Zheng, X. Y., Cao, D. S., Ye, F. Q. and Xiang, Z. (2014) A network pharmacology approach to understanding the mechanisms of action of traditional medicine: Bushenhuoxue formula for treatment of chronic kidney disease. *PLoS One*, 9, e89123
151. Cai, H., Luo, Y., Yan, X., Ding, P., Huang, Y., Fang, S., Zhang, R., Chen, Y., Guo, Z., Fang, J., *et al.* (2018) The mechanisms of Bushen-Yizhi formula as a therapeutic agent against alzheimer's disease. *Sci. Rep.*, 8, 3104
152. Huang, J., Tang, H., Cao, S., He, Y., Feng, Y., Wang, K. and Zheng, Q. (2017) Molecular targets and associated potential pathways of danlu capsules in hyperplasia of mammary glands based on systems pharmacology. *Evid. Based Complement. Alternat. Med.*, 2017, 1930598
153. Luo, Y., Wang, Q. and Zhang, Y. (2016) A systems pharmacology approach to decipher the mechanism of danggui-shaoyao-san decoction for the treatment of neurodegenerative diseases. *J. Ethnopharmacol.*, 178, 66–81
154. Zheng, C. S., Fu, C. L., Pan, C. B., Bao, H. J., Chen, X. Q., Ye, H. Z., Ye, J. X., Wu, G. W., Li, X. H., Xu, H. F., *et al.* (2015) Deciphering the underlying mechanisms of Diesun Miaofang in traumatic injury from a systems pharmacology perspective. *Mol. Med. Rep.*, 12, 1769–1776
155. Xu, H., Zhang, Y., Lei, Y., Gao, X., Zhai, H., Lin, N., Tang, S., Liang, R., Ma, Y., Li, D., *et al.* (2014) A systems biology-based approach to uncovering the molecular mechanisms underlying the effects of dragon's blood tablet in colitis, involving the integration of chemical analysis, ADME prediction, and network pharmacology. *PLoS One*, 9, e101432
156. Li, H., Zhao, L., Zhang, B., Jiang, Y., Wang, X., Guo, Y., Liu, H., Li, S. and Tong, X. (2014) A network pharmacology approach to determine active compounds and action mechanisms of Ge-Gen-Qin-Lian decoction for treatment of type 2 diabetes. *Evid. Based Complement. Alternat. Med.*, 2014, 495840
157. Liang, X., Li, H. and Li, S. (2014) A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study. *Mol. Biosyst.*, 10, 1014–1022
158. Yao, Y., Zhang, X., Wang, Z., Zheng, C., Li, P., Huang, C., Tao, W., Xiao, W., Wang, Y., Huang, L., *et al.* (2013) Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-huang decoction. *J. Ethnopharmacol.*, 150, 619–638
159. Tang, F., Tang, Q., Tian, Y., Fan, Q., Huang, Y. and Tan, X. (2015) Network pharmacology-based prediction of the active ingredients and potential targets of Mahuang Fuzi Xixin decoction for application to allergic rhinitis. *J. Ethnopharmacol.*, 176, 402–412
160. Huang, T., Ning, Z., Hu, D., Zhang, M., Zhao, L., Lin, C., Zhong, L. L. D., Yang, Z., Xu, H. and Bian, Z. (2018) Uncovering the mechanisms of Chinese herbal medicine (MaZiRenWan) for functional constipation by focused network pharmacology approach. *Front. Pharmacol.*, 9, 270
161. Wang, X., Yu, S., Jia, Q., Chen, L., Zhong, J., Pan, Y., Shen, P., Shen, Y., Wang, S., Wei, Z., *et al.* (2017) NiaoDuQing granules relieve chronic kidney disease symptoms by decreasing renal fibrosis and anemia. *Oncotarget*, 8, 55920–55937
162. Ke, Z. P., Zhang, X. Z., Ding, Y., Cao, L., Li, N., Ding, G., Wang, Z. Z. and Xiao, W. (2015) Study on effective substance basis and molecular mechanism of Qigui Tongfeng tablet using network pharmacology method. *Zhongguo Zhongyao Zazhi*, 40, 2837–2842, in Chinese
163. Tao, W., Xu, X., Wang, X., Li, B., Wang, Y., Li, Y. and Yang, L. (2013) Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. *J. Ethnopharmacol.*, 145, 1–10
164. Yang, H., Zhang, W., Huang, C., Zhou, W., Yao, Y., Wang, Z., Li, Y., Xiao, W. and Wang, Y. (2014) A novel systems pharmacology model for herbal medicine injection: a case using reduning injection. *BMC Complement. Altern. Med.*, 14, 430
165. Luo, F., Gu, J., Zhang, X., Chen, L., Cao, L., Li, N., Wang, Z., Xiao, W. and Xu, X. (2015) Multiscale modeling of drug-induced effects of ReDuNing injection on human disease: from drug molecules to clinical symptoms of disease. *Sci. Rep.*, 5, 10064
166. Liu, J., Sun, K., Zheng, C., Chen, X., Zhang, W., Wang, Z., Shar, P. A., Xiao, W. and Wang, Y. (2015) Pathway as a pharmacological target for herbal medicines: an investigation from reduning injection. *PLoS One*, 10, e0123109
167. Wu, L., Wang, Y., Nie, J., Fan, X. and Cheng, Y. (2013) A network pharmacology approach to evaluating the efficacy of Chinese medicine using genome-wide transcriptional expression data. *Evid. Based Complement. Alternat. Med.*, 2013, 915343
168. Shen, X., Zhao, Z., Luo, X., Wang, H., Hu, B. and Guo, Z. (2016) Systems pharmacology based study of the molecular mechanism of SiNiSan formula for application in nervous and mental diseases. *Evid. Based Complement. Alternat. Med.*, 2016, 9146378
169. Wang, H. H., Zhang, B. X., Ye, X. T., He, S. B., Zhang, Y. L. and Wang, Y. (2015) Study on mechanism for anti-depression efficacy

- of Sini San through auxiliary mechanism elucidation system for Chinese medicine. *Zhongguo Zhongyao Zazhi*, 40, 3723–3728, in Chinese
170. Zheng, C. S., Xu, X. J., Ye, H. Z., Wu, G. W., Li, X. H., Xu, H. F. and Liu, X. X. (2013) Network pharmacology-based prediction of the multi-target capabilities of the compounds in Taohong Siwu decoction, and their application in osteoarthritis. *Exp. Ther. Med.*, 6, 125–132
 171. Wang, T., Wu, Z., Sun, L., Li, W., Liu, G. and Tang, Y. (2018) A computational systems pharmacology approach to investigate molecular mechanisms of herbal formula Tian-Ma-Gou-Teng-Yin for treatment of alzheimer's disease. *Front. Pharmacol.*, 9, 668
 172. Li, Y., Zhang, J., Zhang, L., Chen, X., Pan, Y., Chen, S. S., Zhang, S., Wang, Z., Xiao, W., Yang, L., *et al.* (2015) Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula. *J. Ethnopharmacol.*, 174, 45–56
 173. Gao, Y., Gao, L., Gao, X. X., Zhou, Y. Z., Qin, X. M. and Tian, J. S. (2015) An exploration in the action targets for antidepressant bioactive components of Xiaoyaosan based on network pharmacology. *Acta Pharma. Sinica (Yao Xue Xue Bao)*, 50, 1589–1595, in Chinese
 174. Liu, J., Pei, T., Mu, J., Zheng, C., Chen, X., Huang, C., Fu, Y., Liang, Z. and Wang, Y. (2016) Systems pharmacology uncovers the multiple mechanisms of Xijiao Dihuang decoction for the treatment of viral hemorrhagic fever. *Evid. Based Complement. Alternat. Med.*, 2016, 9025036
 175. Pang, H. Q., Yue, S. J., Tang, Y. P., Chen, Y. Y., Tan, Y. J., Cao, Y. J., Shi, X. Q., Zhou, G. S., Kang, A., Huang, S. L., *et al.* (2018) Integrated metabolomics and network pharmacology approach to explain possible action mechanisms of Xin-Sheng-Hua granule for treating Anemia. *Front. Pharmacol.*, 9, 165
 176. Chen, L., Cao, Y., Zhang, H., Lv, D., Zhao, Y., Liu, Y., Ye, G. and Chai, Y. (2018) Network pharmacology-based strategy for predicting active ingredients and potential targets of Yangxinshi tablet for treating heart failure. *J. Ethnopharmacol.*, 219, 359–368
 177. Huang, J., Cheung, F., Tan, H. Y., Hong, M., Wang, N., Yang, J., Feng, Y. and Zheng, Q. (2017) Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology. *Mol. Med. Rep.*, 16, 4583–4592
 178. An, L. and Feng, F. (2015) Network pharmacology-based antioxidant effect study of Zhi-Zi-Da-Huang decoction for alcoholic liver disease. *Evid. Based Complement. Alternat. Med.*, 2015, 492470
 179. Li, F., Lv, Y. N., Tan, Y. S., Shen, K., Zhai, K. F., Chen, H. L., Kou, J. P. and Yu, B. Y. (2015) An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases. *Acta Pharmacol. Sin.*, 36, 1337–1348
 180. Li, B., Tao, W., Zheng, C., Shar, P. A., Huang, C., Fu, Y. and Wang, Y. (2014) Systems pharmacology-based approach for dissecting the addition and subtraction theory of traditional Chinese medicine: an example using Xiao-Chaihu-Decoction and Da-Chaihu-Decoction. *Comput. Biol. Med.*, 53, 19–29
 181. Zhou, W. and Wang, Y. (2014) A network-based analysis of the types of coronary artery disease from traditional Chinese medicine perspective: potential for therapeutics and drug discovery. *J. Ethnopharmacol.*, 151, 66–77
 182. Wang, J., Liu, R., Liu, B., Yang, Y., Xie, J. and Zhu, N. (2017) Systems pharmacology-based strategy to screen new adjuvant for hepatitis B vaccine from traditional Chinese medicine ophiocordyceps sinensis. *Sci. Rep.*, 7, 44788